# Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

> clinical trial · VERIFIED · 2026-07-15

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Non-Small Cell Lung Cancer

- Company: AstraZeneca
- Sector: Non-Small Cell Lung Cancer
- Primary source: https://clinicaltrials.gov/study/NCT06357533

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.